Increased ERK1/2 activation post gemcitabine treatment in gemcitabine resistant pancreatic cancer cells, Bxpc-3, was reported to promote MDR phenotype, which reversed upon combinatorial treatment of gefitinib and gemcitabine [42]. The gene discussed is MAPK3; the disease is familial pancreatic carcinoma.